Health · Pharma & Biotech · 1 day ago
Spain withdraws El Toro supplement after detecting sildenafil
Spain’s medicines agency has ordered the withdrawal of El Toro, a supplement marketed to boost sexual performance.
The agency found that it contains sildenafil, the active ingredient in Viagra, although the product label did not disclose it.
The notification that led to the action came from the police headquarters in Asturias.
Sildenafil can affect blood flow and is used to treat erectile dysfunction.
Because El Toro contains enough of the substance to have an effect, the agency says it counts as a medicine, not just a supplement.
Medicines need prior authorization to be sold in Spain.
The agency has withdrawn the product from sale; no further steps are stated.
Spain’s medicines agency, Aemps, has withdrawn the El Toro supplement from sale after detecting sildenafil.
The agency said the product contained enough sildenafil to produce an effect in the body.
El Toro was marketed as a natural product, but its label did not list sildenafil.
Because it contains the active ingredient, the agency considers El Toro a medicine that requires prior authorization to be sold.
The alert followed a notification from the Asturias police headquarters.
- Who
- Spain’s medicines agency, Aemps, and the El Toro supplement.
- What
- Aemps issued a health alert and withdrew El Toro from sale after detecting sildenafil.
- When
- 10 October 2026. The article was published that day.
- Where
- Spain.
- Why
- El Toro contained sildenafil in an amount sufficient to produce an effect, but its label did not disclose the ingredient.
This story does not have two clearly opposing sides.
No direct quotes in the coverage so far.
The Asturias police headquarters notified Aemps, prompting the agency’s action.
Aemps issued a health alert and withdrew El Toro from sale after detecting sildenafil.
- Product
- El Toro
- Agency
- Spanish Agency of Medicines and Medical Devices (Aemps)
- Detected ingredient
- Sildenafil
- Notification source
- Asturias police headquarters
- Publication date
- 10 October 2026
Sources
Related news
Experimental injection reduced visceral fat by 12% in early trials
AstraZeneca blames trial design for failed bone disease drug study
Baby Sleep Gripe Water Recalled After Alcohol Found in Testing
FDA Warns Amazon Over Unapproved Herpes Treatments
Possible Wrong Dose Raises Questions for PDE9 Drug Trials in Heart Failure
Experimental eye drops improve vision in a small study of a rare eye disease
FDA approves atezolizumab with chemotherapy for some stage III colon cancers
Review links drug company gifts to more and less appropriate prescribing
Brazil suspends Peptistrong supplement and orders all batches recalled
Taboos limit sales of weight-loss drugs in India despite obesity rates
Roche reports year-long results for eye drug Vamikibart
